Tirzepatide (Mounjaro) vs Dulaglutide

While no head-to-head trial directly compared tirzepatide and dulaglutide, both have extensive clinical trial data that allows meaningful cross-trial comparison.

Trulicity was studied in the AWARD program. AWARD-1 through AWARD-11 evaluated dulaglutide across diverse patient populations. At the 1.5 mg dose, dulaglutide typically reduced HbA1c by 1.1% to 1.5% and produced weight loss of 1.5 to 3.0 kg. At the higher 4.5 mg dose (approved in 2020), HbA1c reductions of 1.5-1.9% and weight loss of approximately 4.5 kg were observed. In AWARD-7, dulaglutide demonstrated kidney benefits compared to insulin glargine in patients with moderate-to-severe CKD.

Mounjaro was studied in the SURPASS program. At the 5 mg dose, tirzepatide reduced HbA1c by approximately 2.0% with weight loss of 7-8 kg. At 10 mg, HbA1c reductions were approximately 2.2% with 9-10 kg weight loss. At 15 mg, HbA1c dropped by approximately 2.3-2.6% with 11-13 kg weight loss. In SURPASS-2, the head-to-head versus semaglutide 1 mg, tirzepatide demonstrated superiority at all three doses.

The differences are striking. Mounjaro at its lowest dose (5 mg) produces comparable or greater HbA1c reduction than Trulicity at its highest dose (4.5 mg), with substantially more weight loss. At maximum doses, Mounjaro produces approximately 1.0% more HbA1c reduction and 7-10 kg more weight loss than Trulicity.

For cardiovascular outcomes, Trulicity has completed the REWIND trial, which demonstrated a 12% reduction in 3-point MACE (cardiovascular death, nonfatal MI, nonfatal stroke) in patients with type 2 diabetes, many without established cardiovascular disease. Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. While pre-specified meta-analyses of SURPASS data suggest cardiovascular safety, definitive CVOT results are not yet available.

In summary, Mounjaro produces substantially greater glycemic improvement and weight loss than Trulicity, while Trulicity has the advantage of completed cardiovascular outcomes data.

Both Mounjaro and Trulicity produce gastrointestinal side effects as their most common adverse events, but the profiles differ somewhat in magnitude.

In the AWARD trials for Trulicity, the most common side effects were nausea ^[1][2] (12-21%), diarrhea (8-13%), vomiting (6-12%), abdominal pain (6-9%), and decreased appetite (4-8%). Treatment discontinuation due to adverse events was approximately 2-6%. Trulicity is generally considered to have a favorable GI tolerability profile among GLP-1 agonists.

In the SURPASS trials for Mounjaro, gastrointestinal side effects were somewhat more common, particularly at higher doses. Nausea occurred in 12-25%, diarrhea in 12-17%, vomiting in 5-10%, constipation in 6-11%, and decreased appetite in 5-11%. Treatment discontinuation due to adverse events was 4-7%. Injection site reactions were reported in 3-7% of patients.

Both medications carry the same class-related warnings: thyroid C-cell tumors ^[1][2] (boxed warning), pancreatitis, acute gallbladder disease, hypoglycemia (with insulin or sulfonylureas), acute kidney injury ^[1][2], and hypersensitivity reactions. Both are contraindicated in patients with medullary thyroid carcinoma or MEN 2.

Trulicity has more extensive post-market safety experience given its 10-year approval history (since 2014), providing greater confidence in its long-term safety profile. Mounjaro's post-market experience is still accumulating.

One consideration: patients who have been stable on Trulicity with good tolerability may experience new GI side effects ^[1][2] when switching to Mounjaro, even though both target the GLP-1 receptor, because tirzepatide additionally activates GIP receptors.

Both Mounjaro and Trulicity are brand-name medications from Eli Lilly without generic alternatives.

Trulicity costs approximately $900 per month ^[2] $900-$1,000 per month at list price. Mounjaro costs approximately $1,023 ^[1]-$1,100 per month. Prices are relatively comparable.

Both are covered by most commercial insurance plans and Medicare Part D for type 2 diabetes. Formulary tier placement varies — some plans may prefer the older Trulicity, while others may have favorable Mounjaro coverage. Prior authorization requirements are common for both.

Eli Lilly offers savings programs for both medications. The Trulicity Savings Card and Mounjaro Savings Card can reduce copays to as low as $25 per fill for eligible commercially insured patients. Patient assistance programs are available for qualifying uninsured patients.

Given Mounjaro's substantially greater efficacy at comparable pricing, the cost-effectiveness analysis generally favors Mounjaro for patients who can access it. However, if insurance formulary strongly favors Trulicity with lower copays, the practical cost difference to the patient may be meaningful.

Both Mounjaro and Trulicity are once-weekly subcutaneous injections manufactured by Eli Lilly, using similar autoinjector pen technology.

Trulicity uses a single-dose pen ^[2] available in four strengths: 0.75 mg, 1.5 mg, 3.0 mg, and 4.5 mg. The device features a hidden needle design — the needle is pre-attached and never visible to the patient. Injection is performed by pressing the pen against the skin and clicking. Trulicity pens can be stored at room temperature for up to 14 days.

Mounjaro uses a similar single-dose autoinjector available in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The device design is very similar to Trulicity's, with a hidden needle and push-button operation. Mounjaro autoinjectors can be stored at room temperature for up to 21 days.

The similarity in device design is advantageous for patients switching from Trulicity to Mounjaro — the injection technique is essentially the same. Mounjaro's slightly longer room-temperature storage (21 vs. 14 days) provides a minor practical advantage for travel.

For most patients with type 2 diabetes, the clinical evidence supports Mounjaro as the more effective option when comparing to Trulicity. Mounjaro produces substantially greater HbA1c reductions and significantly more weight loss at all dose levels. The dual GIP/GLP-1 mechanism appears to provide meaningful advantages over GLP-1 agonism alone.

However, Trulicity remains a reasonable choice in several circumstances. For patients who are well-controlled on Trulicity with good tolerability, switching solely based on comparative trial data may not be warranted, especially if the current regimen meets treatment goals. Trulicity has a longer track record with completed cardiovascular outcomes data (REWIND), providing greater long-term safety confidence. Some insurance plans may have more favorable coverage for Trulicity, making it more accessible or affordable. For patients with mild type 2 diabetes who achieve target HbA1c with Trulicity, the additional potency of Mounjaro may not be necessary.

Conversely, patients who are not achieving glycemic targets on Trulicity, those who need significant weight loss alongside diabetes management, or those starting GLP-1-based therapy for the first time may benefit more from Mounjaro.

Patients considering switching from Trulicity to Mounjaro should discuss the transition with their healthcare provider, who will typically start Mounjaro at the 2.5 mg dose and follow the standard titration schedule.

This information is for educational purposes only and does not constitute medical advice. Consult your healthcare provider to determine which medication is most appropriate for your individual situation.